Chin-Yu Lin

745 total citations
8 papers, 494 citations indexed

About

Chin-Yu Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Statistics and Probability. According to data from OpenAlex, Chin-Yu Lin has authored 8 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 2 papers in Oncology and 2 papers in Statistics and Probability. Recurrent topics in Chin-Yu Lin's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Retinal Imaging and Analysis (1 paper). Chin-Yu Lin is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Retinal Imaging and Analysis (1 paper). Chin-Yu Lin collaborates with scholars based in United States, Italy and Germany. Chin-Yu Lin's co-authors include Carlo Albera, Henry N. Hulter, Lisa Lancaster, Paul W. Noble, Ulrich Costabel, Jonathan Polikoff, Bruce E. Johnson, John D. Hainsworth, James Chih‐Hsin Yang and Leonard A. White and has published in prestigious journals such as Journal of Clinical Oncology, Statistics in Medicine and The Lancet Respiratory Medicine.

In The Last Decade

Chin-Yu Lin

8 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chin-Yu Lin United States	7	327	133	107	87	68	8	494
Lawrence Tan Canada	10	218 0.7×	203 1.5×	30 0.3×	35 0.4×	213 3.1×	30	590
Meinrad Mannhart Switzerland	9	132 0.4×	304 2.3×	17 0.2×	13 0.1×	45 0.7×	19	413
Hans M. Westgeest Netherlands	13	189 0.6×	150 1.1×	66 0.6×	10 0.1×	108 1.6×	48	423
Tamjeed Ahmed United States	13	286 0.9×	305 2.3×	20 0.2×	21 0.2×	125 1.8×	32	540
Séverine Sarp Switzerland	9	76 0.2×	196 1.5×	34 0.3×	26 0.3×	119 1.8×	18	398
Sang Hoon Chun South Korea	16	178 0.5×	237 1.8×	73 0.7×	22 0.3×	193 2.8×	54	564
Jules L.L.M. Coenen Netherlands	12	261 0.8×	195 1.5×	160 1.5×	7 0.1×	52 0.8×	20	469
Miriam Rottmann Germany	11	79 0.2×	197 1.5×	100 0.9×	5 0.1×	116 1.7×	23	526
Fermín Person Germany	9	75 0.2×	43 0.3×	12 0.1×	19 0.2×	68 1.0×	11	328
Jennifer B. Permuth United States	13	82 0.3×	230 1.7×	49 0.5×	15 0.2×	112 1.6×	47	412

Countries citing papers authored by Chin-Yu Lin

Since Specialization

Citations

This map shows the geographic impact of Chin-Yu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chin-Yu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chin-Yu Lin more than expected).

Fields of papers citing papers by Chin-Yu Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chin-Yu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chin-Yu Lin. The network helps show where Chin-Yu Lin may publish in the future.

Co-authorship network of co-authors of Chin-Yu Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Chin-Yu Lin. A scholar is included among the top collaborators of Chin-Yu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chin-Yu Lin. Chin-Yu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Khanani, Arshad M., David Callanan, Richard F. Dreyer, et al.. (2020). End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 5(8). 775–787. 56 indexed citations

Costabel, Ulrich, Carlo Albera, Lisa Lancaster, et al.. (2017). An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 94(5). 408–415. 106 indexed citations

Behr, Jürgen, Elisabeth Bendstrup, Bruno Crestani, et al.. (2016). Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 4(6). 445–453. 88 indexed citations

Johnson, Bruce E., Fairooz F. Kabbinavar, Louis Fehrenbacher, et al.. (2013). ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(31). 3926–3934. 138 indexed citations

Danese, Mark D., et al.. (2008). Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clinical Therapeutics. 30(4). 775–784. 17 indexed citations

Meredith, Ruby F., Ronald D. Alvarez, Edward E. Partridge, et al.. (2001). Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 16(4). 305–315. 70 indexed citations

Lin, Chin-Yu, et al.. (2001). Analysis of adverse events in titration studies. Journal of Statistical Planning and Inference. 96(1). 129–142. 2 indexed citations

Palta, Mari & Chin-Yu Lin. (1999). Latent variables, measurement error and methods for analysing longitudinal binary and ordinal data. Statistics in Medicine. 18(4). 385–396. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact